Experiences on Conversion to Once-Daily Advagraf and Sirolimus Combination in Stable Kidney Recipients
- Authors
- Jun, H.; Jung, C. -W.; Kim, M. -G.; Park, K. -T.
- Issue Date
- 3월-2014
- Publisher
- ELSEVIER SCIENCE INC
- Citation
- TRANSPLANTATION PROCEEDINGS, v.46, no.2, pp.400 - 402
- Indexed
- SCIE
SCOPUS
- Journal Title
- TRANSPLANTATION PROCEEDINGS
- Volume
- 46
- Number
- 2
- Start Page
- 400
- End Page
- 402
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/99128
- DOI
- 10.1016/j.transproceed.2014.01.004
- ISSN
- 0041-1345
- Abstract
- In transplant recipients, nephrotoxicity due to long-term use of calcineurin inhibitor (CM) is a serious problem that cannot be overlooked. Medication compliance can cause graft failure in transplant recipients who are bound to long-term medication. In this study, 36 patients who underwent conversion to once-daily Advagraft and sirolimus combination at Korea University Anam Hospital from September 2011 to March 2013 were retrospectively reviewed at 3 and 6 months for laboratory findings, mean arterial pressure (MAP), and so on. After conversion, serum creatinine level and glomerular filtration rate (GFR) decreased significantly at 3 months (P = .024 and P < .001, respectively). Fasting serum glucose level and proteinuria increased significantly at 6 months (P = .016 and P = .030, respectively). The impact of time after conversion at 3 months was significantly related to the increase in postoperative estimated glomerular filtration rate (eGFR). Graft rejection, morbidity, and mortality did not occur within the study period. A once-daily Advagraf and sirolimus regimen can be a novel standard regimen in stable kidney recipients due to its effects in improving renal function and convenience for patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.